Skip to main content
NANJING PHARMACEUTICAL GROUP COMPANY LIMITED logo

NANJING PHARMACEUTICAL GROUP COMPANY LIMITED — Investor Relations & Filings

Ticker · 600713 ISIN · CNE000000KV1 LEI · 300300TIR7I8SWM0SS05 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,539 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600713

About NANJING PHARMACEUTICAL GROUP COMPANY LIMITED

https://www.nanjing-pharma.com/

Nanjing Pharmaceutical Group Company Limited is a large-scale enterprise specializing in the distribution, logistics, and retail of healthcare products. The company operates an extensive supply chain network, providing wholesale services for Western medicines, traditional Chinese medicines, medical devices, and diagnostic reagents. It serves a broad client base including hospitals, community health centers, and retail pharmacies. Key operations include modern pharmaceutical logistics management, third-party logistics services, and the management of a comprehensive retail pharmacy network. The group focuses on integrating digital technology into its supply chain to enhance efficiency in drug procurement and distribution. It also engages in healthcare value-added services, aiming to optimize the pharmaceutical circulation process through professional logistics and information technology solutions.

Recent filings

Filing Released Lang Actions
南京医药关于公司使用部分暂时闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告
Regulatory Filings Classification · 85% confidence The document is a formal public announcement by the company’s board regarding the use of temporarily idle raised funds (募集资金) for cash management products. It details past redemptions, new investment amounts, risk disclosures, and board resolutions. This is not an earnings release, management discussion, or financial report itself, nor does it announce publication of a report. It is a routine regulatory disclosure about business operations and use of proceeds, fitting the General Regulatory Filings (RNS) category.
2026-06-02 Chinese
南京医药集团股份有限公司2026年度跟踪评级报告
Regulatory Filings Classification · 30% confidence The document is a comprehensive credit rating report (“2026年度跟踪评级报告”) prepared by China Chengxin International Credit Rating Co., Ltd. for Nanjing Pharmaceutical Group Co., Ltd. It is neither an annual/quarterly financial report by the company nor an audit report or investor presentation. It primarily contains rating opinions, methodology, bond and credit ratings, and detailed financial analysis by an external rating agency. There is no specific category for credit rating reports in the taxonomy, so it defaults to the general Regulatory Filings (RNS) category as a fallback.
2026-06-02 Chinese
南京医药关于可转换公司债券2026年度跟踪评级结果的公告
Regulatory Filings Classification · 62% confidence The document is a short (under 1,000 characters) public announcement (“公告”) disclosing the results of the 2026 annual credit‐rating review for the company’s convertible bonds. It does not contain substantive financial statements or detailed report content, but merely announces the rating outcome and directs readers to the full report on the exchange website. It is not an AGM presentation, earnings release, management report, or a formal financial statement, but a routine regulatory disclosure. Under the classification rules, such miscellaneous announcements fall into the Regulatory Filings (RNS) category.
2026-06-02 Chinese
南京医药2026年度第七期超短期融资券发行结果公告
Capital/Financing Update Classification · 95% confidence The document is an issuance results announcement (“发行结果公告”) for the company’s issuance of short‐term financing bonds (超短期融资券), detailing the bond issuance amount, rate, dates, and underwriters. This is a 核心债券融资活动 update rather than a financial report or board change or share issue. This falls squarely under Capital/Financing Update (CAP).
2026-05-28 Chinese
南京医药关于召开2026年第三次临时股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal announcement by the board of Nanjing Pharmaceutical Group Co., Ltd. calling and providing details for the 2026 third Extraordinary General Meeting of shareholders, including meeting date, voting methods, agenda items, proxy procedures and registration details. It is not the minutes or results of the meeting but the solicitation of proxies and information for shareholders to vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-28 Chinese
南京医药2026年度第一期中期票据发行结果公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement of the issuance results for the company’s 2026 first tranche medium-term notes. It includes detailed financing terms: registered amount, issue date, maturity, interest rate, underwriters, and use of proceeds. This falls squarely under capital/financing updates rather than an equity share change or an earnings report.
2026-05-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.